Loss of FHIT expression in breast cancer is correlated with poor prognostic markers

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 7, 2005, Pages 1681-1685

  Arun, Banu ^a,c   Kilic, Gokhan ^a   Yen, Charles ^a   Foster, Barbara ^b   Yardley, Denise A ^a   Gaynor, Richard ^a   Ashfaq, Raheela ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; CYCLOOXYGENASE 2; FRAGILE HISTIDINE TRIAD PROTEIN; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER GRADING; CHROMOSOME LOSS; DIAGNOSTIC VALUE; FEMALE; FHIT GENE; GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

ACID ANHYDRIDE HYDROLASES; BREAST NEOPLASMS; CYCLOOXYGENASE 2; FEMALE; GENES, BCL-2; HUMANS; LYMPHATIC METASTASIS; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 22244468667     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-04-0278     Document Type: Article

References (29)

1. Ohta M, Inoue H, Cotticelli MG, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 1996;84:587-97.
2. Croce CM, Sozzi G, Huebner K. Role of FHIT in human cancer. J Clin Oncol 1999;17:1618-24.
3. Negrini M, Monaco C, Vorechovsky I, et al. The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res 1996;56:3173-9.
4. Huebner K, Garrison PN, Barnes LD, Croce CM. The role of the FHIT/ FRA3B locus in cancer. Annu Rev Genet 1998;32:7-31.
5. Greenspan DL, Connolly DC, Wu R, et al. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Res 1997;57: 4692-8.
6. Campiglio M, Pekarsky Y, Menard S, Tagliabue E, Pilotti S, Croce CM. FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Res 1999;59:3866-9.
7. Sozzi G, Pastorino U, Moiraghi L, et al. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res 1998;58:5032-7.
8. Hadaczek P, Siprashvili Z, Markiewski M, et al. Absence or reduction of Fhit expression in most clear cell renal carcinomas. Cancer Res 1998;58:2946-51.
9. Ingvarsson S, Agnarsson BA, Sigbjornsdottir BI, et al. Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas. Cancer Res 1999;59:2682-9.
10. Ahmadian M, Wistuba II, Fong KM, et al. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res 1997;57:3664-8.
11. Man S, Ellis IO, Sibbering M, Blamey RW, Brook JD. High levels of allele loss at the FHIT and ATM genes in non-comedo ductal carcinoma in situ and grade I tubular invasive breast cancers. Cancer Res 1996;56:5484-9.
12. Zochbauer-Muller S, Fong KM, Maitra A, et al. 5′ CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res 2001;61:3581-5.
13. Hayashi S, Tanimoto K, Hajiio-Nakanishi K, et al. Abnormal FHIT transcripts in human breast carcinomas: a clinicopathological and epidemiological analysis of 61 Japanese cases. Cancer Res 1997;57:1981-5.
14. Gatalica Z, Lele SM, Rampy BA, Norris BA. The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma. Cancer 2000;88:1378-83.
15. Yang Q, Yoshimura G, Suzuma T, et al. Clinicopathological significance of fragile histidine triad transcription protein expression in breast carcinoma. Clin Cancer Res 2001;7:3869-73.
16. Ingvarsson S, Sigbjornsdottir BI, Huiping C, Jonasson JG, Agnarsson BA. Alterations of the FHIT gene in breast cancer: association with tumor progression and patient survival. Cancer Detect Prev 2001;25:292-8.
17. Parrett M, Harris R, Joarder F, Ross MS, Clausen K, Robertson F. Cyclooxygenase-2 gene expression in human breast cancer. Int J Oncol 1997;10:503-7.
18. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-11.
19. Arun B, Foster B, Yen C, Kilic G, Gaynor R, Ashfaq R. Cyclooxygenase-2 expression in breast cancer and metastatic lymph node. Proc Am Soc Clin Oncol 2001;20:1781a.
20. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998;90: 455-60.
21. Denkert C, Winzer KJ, Muller BM, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 2003;97:2978-87.
22. Barnes LD, Garrison PN, Siprashvili Z, et al. Fhit, a putative tumor suppressor in humans, is a dinucleoside 5′,5′″-P1,P3- triphosphate hydiolase. Biochemistry 1996;35:11529-35.
23. Siprashvili Z, Sozzi G, Barnes LD, et al. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci U S A 1997;94:13771-6.
24. Ingvarsson S, Geirsdottir EK, Johannesdottir G, et al. High incidence of loss of heterozygosity in breast tumors from carriers of the BRCA2 999del5 mutation. Cancer Res 1998;58:4421-5.
25. Buchhagen DL, Qiu L, Etkind P. Homozygous deletion, rearrangement and hypermethylation implicate chromosome region 3p14.3-3p21.3 in sporadic breast-cancer development. Int J Cancer 1994;57:473-9.
26. Panagopoulos I, Pandis N, Thelin S, et al. The FHIT and PTPRG genes are deleted in benign proliferative breast disease associated with familial breast cancer and cytogenetic rearrangements of chromosome band 3p14. Cancer Res 1996;56:4871-5.
27. Costa S-D, Lange S, Klinga K, Merkle E, Kaufmann M. Factors influencing the prognostic role of oestrogen and progesterone receptor levels in breast cancer-results of the analysis of 670 patients with 11 years of follow-up. Eur J Cancer 2002;38:1329-34.
28. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cydooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632-5.
29. Sard L, Accornero P, Tornielli S, et al. The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci U S A 1999;96:8489-92.